Rituximab is associated with improved survival in Burkitt lymphoma: A retrospective analysis from two US academic medical centers

Therapeutic Advances in Hematology

Volumn 5, Issue 1, 2014, Pages 3-12

  Wildes, Tanya M ^a   Farrington, Laura ^b   Yeung, Cecilia ^c   Harrington, Alexandra M ^d   Foyil, Kelley V ^a   Liu, Jingxia ^a   Bartlett, Nancy L ^a   Kreisel, Friederike ^a   Fenske, Timothy S ^d  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b East Tennessee State University   (United States)

^c Fred Hutchinson Cancer Research Center   (United States)

^d MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

Burkitt lymphoma; chemotherapy; rituximab; survival

Indexed keywords

EID: 84993683928     PISSN: 20406207     EISSN: 20406215     Source Type: Journal    
DOI: 10.1177/2040620713514682     Document Type: Review

References (29)

1. Barnes J. Lacasce A. Feng Y. Toomey C. Neuberg D. Michaelson J. et al. (2011) Evaluation of the addition of rituximab to CODOX-M/IVAC for Burkitt's lymphoma: a retrospective analysis. Ann Oncol 22: 1859–1864.
2. Bennett J. Catovsky D. Daniel M. Flandrin G. Galton D. Gralnick H. et al. (1985) Proposed revised criteria for the classification of acute myeloid leukemia A report of the French-American-British Cooperative Group. Ann Int Med 103: 620–625.
3. Blayney D. LeBlanc M. Grogan T. Gaynor E. Chapman R. Spiridonidis C. et al. (2003) Dose-intense chemotherapy every 2 weeks with dose-intense cyclophosphamide, doxorubicin, vincristine, and prednisone may improve survival in intermediate- and high-grade lymphoma: a phase II Study of the Southwest Oncology Group (SWOG 9349). J Clin Oncol 21: 2466–2473.
4. Castillo J. Winer E. Olszewski A. (2013) Population-based prognostic factors for survival in patients with Burkitt lymphoma: An analysis from the Surveillance, Epidemiology, and End Results database. Cancer 119: 3672–3679.
5. Cheson B. Horning S. Coiffier B. Shipp M. Fisher R. Connors J. et al. (1999) Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 17: 1244–1253.
6. Coiffier B. Lepage E. Brière J. Herbrecht R. Tilly H. Bouabdallah R. et al. (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346: 235–242.
7. Costa L. Xavier A. Wahlquist A. Hill E. (2013) Trends in survival of patients with Burkitt lymphoma / leukemia in the USA: an analysis of 3691 cases. Blood 121: 4861–4866.
8. Dave S. Fu K. Wright G. Lam L. Kluin P. Boerma E. et al. (2006) Molecular diagnosis of Burkitt's lymphoma. N Engl J Med 354: 2431–2442.
9. Dujmovic D. Aurer I. Radman I. Serventi-Seiwerth R. Dotlic S. Stern-Padovan R. et al. (2012) Addition of rituximab to high-dose methotrexate-based chemotherapy improves survival of adults with Burkitt lymphoma/leukemia. Acta Haematologica 127: 115–117.
10. Dunleavy K. Pittaluga S. Wayne A. Shovlin M. Johnson J. Little R. et al. (2011) Myc+ aggressive B-cell lymphomas: novel therapy of untreated Burkitt lymphoma (BL) and Myc+ diffuse large B-cell lymphoma (DLBCL) with DA-EPOCH-R. Ann Oncol 22 (54): 71.
11. Evens A. Carson K. Kolesar J. Nabhan C. Helenowski I. Islam N. et al. (2013) A multicenter phase II study incorporating high-dose rituximab and liposomal doxorubicin into the CODOX-M/IVAC regimen for untreated Burkitt's lymphoma. Ann Oncol, in press.
12. Fayad L. Thomas D. Romaguera J. (2007) Update of the M.D. Anderson Cancer Center experience with hyper-CVAD and rituximab for the treatment of mantle cell and Burkitt-type lymphomas. Clin Lymph Myeloma 8(Suppl. 2): S57–S62.
13. Harris N. Jaffe E. Diebold J. Flandrin G. Müller-Hermelink H. Vardiman J. et al. (1999) The World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. Report of the Clinical Advisory Committee meeting, Airlie House, Virginia, November, 1997. Ann Oncol 10: 1419–1432.
14. Hummel M. Bentink S. Berger H. Klapper W. Wessendorf S. Barth T. et al. (2006) A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling. N Engl J Med 354: 2419–2430.
15. Kantarjian H. Walters R. Keating M. Smith T. O'Brien S. Estey E. et al. (1990) Results of the vincristine, doxorubicin, and dexamethasone regimen in adults with standard- and high-risk acute lymphocytic leukemia. J Clin Oncol 8: 994–1004.
16. Kelly J. Toothaker S. Ciminello L. Hoelzer D. Holte H. LaCasce A. et al. (2009) Outcomes of patients with Burkitt lymphoma older than age 40 treated with intensive chemotherapeutic regimens. Clin Lymph Myeloma 9: 307–310.
17. Maruyama D. Watanabe T. Maeshima A. Nomoto J. Taniguchi H. Azuma T. et al. (2010) Modified cyclophosphamide, vincristine, doxorubicin, and methotrexate (CODOX-M)/ifosfamide, etoposide, and cytarabine (IVAC) therapy with or without rituximab in Japanese adult patients with Burkitt lymphoma (BL) and B cell lymphoma, unclassifiable, with features intermediate between diffuse large B cell lymphoma and BL. Int J Hematol 92: 732–743.
18. Mead G. Sydes M. Walewski J. Grigg A. Hatton C. Norbert P. et al. (2002) An international evaluation of CODOX-M and CODOX-M alternating with IVAC in adult Burkitt's lymphoma: Results of United Kingdom Lymphoma Group LY 06 study. Ann Oncol 13: 1264–1274.
19. Pfreundschuh M. Trümper L. Österborg A. Pettengell R. Trneny M. Imrie K. et al. (2006). CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 7: 379–391.
20. Ribrag V. Koscielny S. Bouabdallah K. Salles G. Casasnovas O. Recher C. et al. (2012) Addition of rituximab improves outcome of HIV negative patients with Burkitt lymphoma treated with the LMBA protocol: results of the Randomized Intergroup (GRAALL-Lysa) LMBA 02 Protocol. Blood (ASH Annual Meeting Abstracts) 120: 685a.
21. Rizzieri D. Johnson J. Niedzwiecki D. Lee E. Vardiman J. Powell B. et al. (2004) Intensive chemotherapy with and without cranial radiation for Burkitt leukemia and lymphoma: final results of Cancer and Leukemia Group B Study 9251. Cancer 100: 1438–1448.
22. Rosenbaum P. Rubin D. (1983) The central role of the propensity score in observational studies for causal effects. Biometrika 70: 41–55.
23. Swerdlow S. Campo E. Harris N. Jaffe E. Pileri S. Stein H. et al. (2008) WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: International Agency for Research on Cancer.
24. The Non-Hodgkin's Lymphoma Classification Project (1982) National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: summary and description of a working formulation for clinical usage. Cancer 49: 2112–2135.
25. Thomas D. Cortes J. O'Brien S. Pierce S. Faderl S. Albitar M. et al. (1999) Hyper-CVAD program in Burkitt's-type adult acute lymphoblastic leukemia. J Clin Oncol 17: 2461–2470.
26. Thomas D. Faderl S. O'Brien S. Bueso-Ramos C. Cortes J. Garcia-Manero G. et al. (2006) Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. Cancer 106: 1569–1580.
27. Todeschini G. Bonifacio M. Tecchio C. Balter R. Carli G. Stefani P. et al. (2012) Intensive short-term chemotherapy regimen induces high remission rate (over 90%) and event-free survival both in children and adult patients with advanced sporadic Burkitt lymphoma/leukemia. Am J Hematol 87: 22–25.
28. Wästerlid T. Brown P. Hagberg O. Hagberg H. Pedersen L. D'Amore F. et al. (2013) Impact of chemotherapy regimen and rituximab in adult Burkitt lymphoma: a retrospective population-based study from the Nordic Lymphoma Group. Ann Oncol 24: 1879–1886.
29. Wästerlid T. Jonsson B. Hagberg H. Jerkeman M. (2011) Population based study of prognostic factors and treatment in adult Burkitt lymphoma: a Swedish Lymphoma Registry study. Leuk Lymph 52: 2090–2096.